Stone Pharmaceuticals (300765.SZ) controlled subsidiary SYS6043 initiates Phase III clinical trial.

Zh tng cijng APP xn, sh yo chung xn (300765.SZ) fb gnggo, gngs kngg zgngs sh yo jtun j sh shngw zhyo yuxin gngs (jinchng "j sh shngw") y y jnr qdng y xing pngji SYS6043 dub ynjizh xunz de hulio yngy b nidu wnq ldiyn, yunfxng fm i yj shluntng i cnjizh de suj, du zhngxn, kifng binqin de q lnchung shyn. Smart financial APP news, Shiyao Innovation (300765.SZ) announced that its controlling subsidiary Shiyao Group Jiushi Biopharmaceutical Co., Ltd. ("Jiushi Biopharm") has recently initiated a randomized, multicenter, open-label Phase III clinical trial evaluating SYS6043 compared with the chemotherapy selected by researchers for participants with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.